| INDUSTRY NEWS | First Patient in Next Dose Cohort Successfully Treated with ReN001 Stem Cell Therapy ReNeuron provides an update on progress with the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients. [ReNeuron] Press Release Novartis Receives EU Approval for Votubia®, the First Medication to Treat Children and Adults with SEGA Associated with TSC Novartis announced that the European Commission has approved Votubia® (everolimus) tablets for the treatment of patients aged 3 years and older, with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC), who require therapeutic intervention but are not amenable to surgery. [Novartis AG] Press Release Stem Cell Efforts to Treat Neurological Disease Bolstered With $4.5 Million Researchers have received $4.5 million in new funding to further the efforts to use stem cells and related molecules to treat several feared disorders for which there are currently no cures – including multiple sclerosis, Huntington’s disease, and fatal childhood diseases known as pediatric leukodystrophies. [University of Rochester Medical Center] Press Release Rett Syndrome Research Trust Creates MECP2 Consortium The Rett Syndrome Research Trust announced the creation of the MECP2 Consortium, a dynamic collaboration between the laboratories of three distinguished scientists, Adrian Bird, Michael Greenberg and Gail Mandel. [Rett Syndrome Research Trust] Press Release Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington’s Disease Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to Huntington’s disease utilizing Galenea’s proprietary synaptic transmission drug discovery platform. [CHDI Foundation, Inc.] Press Release The Centre for Drug Research and Development and the Brain Research Centre Collaborate to Bring New Therapies to Those Suffering from Neurological Disorders The two organizations will work together, sharing their resources and expertise to facilitate joint drug development research projects — focusing on the acceleration of discovery, development and commercialization of technologies for the diagnosis and treatment of neurological and psychiatric disorders. [Centre for Drug Research and Development] Press Release |
|
|
|